Table 2 Ongoing projects on miRNA-based therapeutics
Drug name | Drug type | Target miR | Disorder | Clinical trial number/phase | Company |
|---|---|---|---|---|---|
Miravirsen | AntagomiR | miR-122 | Hepatitis C | NCT02452814/phase 2 complete NCT01200420/phase 2 (complete) | Roche/Santaris |
MRG-201 (Remlarsen) | miRNA mimic | miR-29b | Fibrosis, keloid | NCT03601052/phase 2 (recruiting) | Miragen Therapeutics (now Synlogic) |
MRG-106 (cobomarsen) | AntagomiR | miR-155 | T cell lymphoma | NCT03713320/phase 2 (recruiting) | Miragen Therapeutics (now Synlogic) |
MRG-110 | AntagomiR | miR-92 | Heart failure | NCT03603431/phase 1 (recruiting) | Miragen Therapeutics (now Synlogic) |
Mesomir-1 | miRNA mimic | miR-16 | Mesothelioma | NCT02369198/phase 1 (complete) | ENGeneIC |
ABX464 | miRNA mimic | miR-124 | Ulcerative colitis | NCT04023396/phase 2 (recruiting) | Abivax |